Alkylphospholipids - A promising class of chemotherapeutic agents with a broad pharmacological spectrum

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 16, Issue 5, 2013, Pages 742-759

  Pachioni, Juliana de Almeida ^a   Magalhães, Juliana Gallottini ^a   Lima, Elys Juliane Cardoso ^a   de Moura Bueno, Luciana ^a   Barbosa, Joyce Ferreira ^a   de Sá, Matheus Malta ^a   Rangel Yagui, Carlota de Oliveira ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACRYLIC ACID COPOLYMER; ALKYLPHOSPHOLIPID DERIVATIVE; AMPHOTERICIN B LIPID COMPLEX; ANTIINFECTIVE AGENT; ANTIMONY; ANTINEOPLASTIC AGENT; BENZNIDAZOLE; BORTEZOMIB; DEXAMETHASONE; EDELFOSINE; ERUCYLPHOSPHOCHOLINE; ERUFOSINE; ILMOFOSINE; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN; METRONIDAZOLE; MILTEFOSINE; NIFURTIMOX; NITROPRUSSIDE SODIUM; PAROMOMYCIN; PERIFOSINE; PHOSPHOLIPID DERIVATIVE; PLACEBO; PROTEIN KINASE B; QUATERNARY AMMONIUM DERIVATIVE; TEMSIROLIMUS; UNCLASSIFIED DRUG;

AFRICAN TRYPANOSOMIASIS; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROTOZOAL ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; BACTERIUM; BREAST CANCER; BREAST METASTASIS; CANCER INHIBITION; CHAGAS DISEASE; CHRONIC URTICARIA; CRITICAL MICELLE CONCENTRATION; DRUG COATING; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENTIATION; DRUG SCREENING; DRUG STRUCTURE; DRUG WITHDRAWAL; FUNGUS; GASTROINTESTINAL TOXICITY; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LENS IMPLANT; LIPID METABOLISM; METASTATIC COLORECTAL CANCER; METASTATIC MELANOMA; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIPLE MYELOMA; NEOPLASM; NEUROBLASTOMA; NONHUMAN; OVARY CARCINOMA; PANCREAS ADENOCARCINOMA; PARASITOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN SYNTHESIS INHIBITION; REVIEW; SCHISTOSOMA MANSONI; SKIN LEISHMANIASIS; SKIN METASTASIS; SOFT TISSUE SARCOMA; SOLID TUMOR; STRUCTURE ANALYSIS; TRICHOMONAS VAGINALIS; TRYPANOSOMA; URTICARIA; VISCERAL LEISHMANIASIS; WALDENSTROEM MACROGLOBULINEMIA;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC AGENTS; BACTERIAL INFECTIONS; HUMANS; MYCOSES; NEOPLASMS; PARASITIC DISEASES; PHOSPHOLIPIDS; QUATERNARY AMMONIUM COMPOUNDS;

EID: 84891097577     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3cw23     Document Type: Review

References (150)

1. van Blitterswijk WJ, Verheij M. Anticancer mechanisms and clinical application of alkylphospholipids. Biochim Biophys Acta, 2012; 1831(8): 663-674.
2. Eibl RH, Arnold D, Weltzien HU, Westphal O. On the synthesis of alpha beta lecithins and their analogs. Justus Liebigs Ann Chem, 1967; 704: 226-230.
3. Andreesen R, Modolell M, Weltzien HU, Eibl H, Common HH, Löhr GW et al. Selective destruction of human leukemic cells by alkyllysophospholipids. Cancer Res, 1978; 38: 3894-3899.
4. Munder PG, Modolell M, Andreesen R, Weltzien HU, Westphal O. Lysophosphatidylcholine (lysolecthin) and its synthetic analogues. Immunomodulating and other biologic effects. Springer Seminars in Immunopathology, 1979; 2: 187-203.
5. Runge MH, Andreesen R, Pfleiderer A, Munder PG. Destruction of human solid tumors by alkyl lysophospholipids. J Natl Cancer Inst,1980; 64(6): 1301-1306.
6. Mollinedo F, Fernández-Luna JL, Gajate C, Martín-Martín B, Benito A, Martínez-Dalmau R et al. Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (Edelfosine): Molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-X(L). Cancer Res, 1997; 57(7): 1320-1328.
7. Mollinedo F, de la Iglesia-Vicente J, Gajate C, Estella-Hermoso de Mendoza A, Villa-Pulgarin JA, de Frias M, et al. In vitro and in vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leucemia involving lipids rafts. Clin. Cancer Res, 16 (2010) 2046-2054.
8. Ruiter GA, Zerp SF, Bartelink H, van Blitterswijk WJ, Verheij M. Alkyllysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer Res, 1999; 59(10): 2457-2463.
9. Berdel WE, Bausert WR, Weltzien HU, Modolell ML, Widmann KH, Munder PG. The influence of alkyl-lysophospholipids and lysophospholipidsactivated macrophages on the development of metastasis of 3-Lewis lung carcinoma. Eur J Cancer, 1980; 16(9): 1199-1204.
10. Tarnowski GS, Mountain IM, Stock CC, Munder PG, Weltzien HU, Westphal O. Effect of lysolecithin and analogs on mouse ascites tumors. Cancer Res, 1978; 38(2): 339-344.
11. Scherf HR, Schuler B, Berger MR, Schmähl D. Therapeutic activity of ET-18-OCH3 and hexadecylphosphocholine against mammary tumors in BD-VI rats. Lipids, 1987; 22(11): 927-929.
12. Berdel WE, Fink U, Rastetter J. Clinical phase I pilot study of the alkyl lysophospholipid derivative ET-18-OCH3. Lipids, 1987; 22(11): 967-969.
13. Dorlo TP, Balasegaram M, Beijnen JH, de Vries PJ. Miltefosine: a review of it pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother, 2012; 67(11): 2576-2597.
14. Breiser A, Kim D J, Fleer E A, Damenz W, Drube A, Berger M, et al. Distribuition and metabolism of hexadecylphosphocholine in mice. Lipids, 1987; 22(11): 925-926.
15. Unger C, Damenz W, Fleer E A, Kim D J, Breiser A, Hilgard P, et al. Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplasic activity in vitro e in vivo. Acta Oncol, 1989; 28(2): 213-217.
16. Verweij J, Gandia D, Planting AS, Stoter G, Armand JP. Phase II study of oral miltefosine in patients with squamous cell head and neck cancer. Eur J Cancer, 1993; 29A(5):778-779.
17. Crul M, Rosing H, de Klerk GJ, Dubbelman R, Traiser M, Reichert S, et al. Phase I and pharmacological study of a daily oral administration of perifosine (d-21266) in patients with advanced solid tumors. Eur J Cancer, 2002; 38(12): 1615-1621.
18. Hilgard P, Klenner T, Stekar J, Nössner G, Kutscher B, Engel J. D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur J Cancer, 1997; 33(3): 442-446.
19. S Vink SR, Schellens JH, van Blitterswijk WJ, Verheij M. Tumor and normal tissue pharmacokinects of perifosine, an oral anticancer alkylphospholipid. Invest New Drugs, 2005; 23(4): 279-286.
20. Berger MR, Konstantinov SM, Eibl RH. Erucylphosphocholine is the prototype of i.v. injectable alkylphosphocholines. Drugs Today, 1998; 34: 73-81.
21. Kaufmann-Kolle P, Berger MR, Unger C, Eibl H. Systemic administration of alkylphosphocholines. Erucylphosphocholine and liposomal hexadecylphosphocholine. Adv Exp Med Biol, 1996; 416: 165-168.
22. Jendrossek V, Hammersen K, Erdlenbruch B, Kugler W, Krügener R, Eibl H, et al. Strutureactivity relationships of alkylphosphocholine derivatives: antineoplastic action on brain tumor cell lines in vitro. Cancer Chemother Pharmacol, 2002; 50(1): 71-79.
23. R Bagley RG, Kurtzberg L, Rouleau C, Yao M, Teicher BA. Erufosine, an alkylphosphocholine, with differential toxicity to human cancer cells and bone marrow cells. Cancer Chemother Pharmacol, 2011; 68(6): 1537-1546.
24. Fiegl M, Lindner LH, Juergens M, Eibl H, Hiddemann W, Braess J. Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: Single activity and combination with other antileukemic drugs. Cancer Chemother Pharmacol, 2007; 62(2): 321-329.
25. Papazafiri P, Avlonitis N, Angelou P, Calogeropoulou T, Koufaki M, Scoulica E, et al. Structure-activity relationships of antineoplastic ring-substituted ether phospholipid derivates. Cancer Chemother Pharmacol, 2005; 56(3):261-270.
26. Heerklotz H. Interactions of surfactants with lipid membranes. Q Rev Biophys, 2008;41(3-4):205-264.
27. Schreier S, Malheiros SV, de Paula E. Surface active drugs: self-association and interaction with membranes and surfactants. Physicochemical and biological aspects. Biochim Biophys Acta, 2000; 1508(1-2):210-234.
28. Preté PS, Gomes K, Malheiros SV, Meirelles NC, de Paula E. Solubilization of human erythrocyte membranes by non-ionic surfactants of the polyoxyethylene alkyl ethers series. Biophys Chem, 2002; 97(1):45-54.
29. Strassheim D, Shafer SH, Phelps SH, Williams CL. Small cell lung carcinoma exhibits greater phospholipase C-ß1 expression and edelfosine resistance compared with non-small cell lung carcinoma. Cancer Res, 2000; 60(10): 2730-2736.
30. van Blitterswijk WJ, Verheij M. Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects. Curr Pharm Des, 2008; 14(21): 2061-2074.
31. van der Luit A H, Vink S R, Klarenbeek J B, Perrissoud D, Solary E, Verheij M et al. A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells. Mol Cancer Ther, 2007; 6(8): 2337-2345.
32. Nieto-Miguel T, Fonteriz RI, Vay L, Gajate C, López-Hernández S, Mollinedo F. Endoplasmic reticulum stress in the proapoptotic action of edelfosine in solid tumor cells. Cancer Res, 2007; 67(21): 10368-10378.
33. van der Sanden MH, Meems H, Houweling M, Helms JB, Vaandrager AB. Induction of CCAAT/enhancer-binding protein (C/EBP)-homologous protein/growth arrest and DNA damage-inducible protein 153 expression during inhibition of phosphatidylcholine synthesis is mediated via activation of a C/EBP-activating transcription factor-responsive element. J Bio Chem, 2004; 279(50): 52007-52015.
34. Ruiter GA, Verheij M, Zerp SF, van Blitterswijk WJ. Alkyl-lysophospholipids as anti-cancer agents and enhancers of radiation-induced apoptosis. Int J Radiat Oncol Biol Phys, 2001; 49(2): 415-419.
35. Dineva IK, Zaharieva MM, Konstantinov SM, Eibl H, Berger MR. Erufosine suppresses breast cancer in vitro and in vivo for its activity on PI3K, c-Raf and Akt proteins. J Cancer Res ClinOncol, 2012; 138(11): 1909-1917.
36. van der Luit AH, Budde M, Ruurs P, Verheij M, van Blitterswijk WJ. Alkyl-lysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis. J Biol Chem, 2002; 277(42): 39541-39547.
37. A Van Der Luit AH, Budde M, Verheij M, Van Blitterswijk WJ. Different modes of internalization of apoptotic alkyllysophospholipid and cell-rescuing lysophosphatidylcholine. Biochem J, 2003; 374(Pt 3): 747-753.
38. Marco C, Jiménez-López JM, Ríos-Marco P, Segovia JL, Carrasco MP. Hexadecylphosphocholine alters nonvesicular cholesterol traffic from the plasma membrane to the endoplasmic reticulum and inhibits the synthesis of sphingomyelin in HepG2 cells. Int J Biochem Cell Biol, 2009; 41(6): 1296-1303.
39. Carrasco MP, Jiménez-López JM, Ríos-Marco P, Segovia JL, Marco C. Disruption of cellular cholesterol transport and homeostasis as a novel mechanism of action of membrane-targeted alkylphospholipid analogues. Br J Pharmacol, 2010; 160(2): 355-366.
40. Li Z, Tan F, Liewehr DJ, Steinberg SM, Thiele CJ. Thiele. In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine. J Natl Cancer Inst, 2010; 102(11): 758-770.
41. Richardson PG, Eng C, Kolesar J, Hideshima T, Anderson KC. Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opin Drug MetabToxicol, 2012; 8(5): 623-633.
42. Gills JJ, Dennis PA. Perifosine: Update on a novel Akt inhibitor. CurrOncol Rep, 2009; 11(2): 102-110.
43. Fu L, Kim Y A, Wang X, Wu X, Yue P, Lonial S et al. Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res, 2009; 69(23): 8967-8976.
44. Alam MM, Joh EH, Park H, Kim B, Kim DH, Lee YS. Synthesis, characterization and Akt phosphorylation inhibitory activity of cyclopentanecarboxylate-substituted alkylphosphocholines. Bioorg Med Chem, 2013; 21(7): 2018-2024.
45. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther, 2003; 2(11): 1093-1103.
46. Hennessy B T, Lu Y, Poradosu E, Yu Q, Yu S, Hall H, et al. Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res, 2007; 13(24): 7421-7431.
47. Kim AH, Khursigara G, Sun X, Franke TF, Chao MV. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol, 2001; 21(3): 893-901.
48. Yuan ZQ, Feldman RI, Sussman GE, Coppola D, Nicosia SV, Cheng JQ. AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: Implication of AKT2 in chemoresistance. J Biol Chem, 2003; 278(26): 23432-23440.
49. Sun W, Modak S. Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine. Onco Targets Ther, 2012; 5: 21-29.
50. Chen M B, Wu X Y, Tao G Q, Liu C Y, Chen J, Wang L Q et al. Perifosine sensitizes curcumininduced anti-colorectal cancer effects by targeting multiple signaling pathways both in vivo and in vitro. Int J Cancer, 2012; 131(11): 2487-2498.
51. Wagner BA, Buettner GR, Burns CP. Increased generation of lipid-derived and ascorbate free radicals by L1210 cells exposed to the ether lipid edelfosine. Cancer Res, 1993; 53(4): 711-713.
52. Ji C, Yang Y L, Yang Z, Tu Y, Cheng L, Chen B et al. Perifosine sensitizes UVB-induced apoptosis in skin cells: New implication of skin cancer prevention? Cell Signal, 2012; 24(9): 1781-1789.
53. Ichijo H, Nishida E, Irie K, ten Dijke P, Saitoh M, Moriguchi T et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science, 1997; 275(5296): 90-94.
54. Nagai H, Noguchi T, Takeda K, Ichijo H. Pathophysiological roles of ASK1-MAP kinase signaling pathways. J Biochem Mol Biol, 2007; 40(1): 1-6.
55. Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ, 2003; 10(1): 26-35.
56. Algeciras-Schimnich A, Shen L, Barnhart BC, Murmann AE, Burkhardt JK, Peter ME. Molecular ordering of the initial signaling events of CD95. Mol Cell Biol, 2002; 22(1): 207-220.
57. Eramo A, Sargiacomo M, Ricci-Vitiani L, Todaro M, Stassi G, Messina C G M et al. CD95 death-inducing signaling complex formation and internalization occur in lipid rafts of type I and type II cells. Eur J Immunol, 2004; 34(7): 1930-1940.
58. Gajate C, Mollinedo F. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood, 2007; 109(2): 711-719.
59. Gajate C, Fonteriz R I, Cabaner C, Alvarez-Noves G, Alvarez-Rodriguez Y, Modolell M et al. Intracellular triggering of Fas, independently of FasL, as a new mechanism of antitumor ether lipid-induced apoptosis. Int J Cancer, 2000; 85(5): 674-682.
60. Mollinedo F, de la Iglesia-Vicente J, Gajate C, Estella-Hermoso de Mendoza A, Villa-Pulgarin J A, Campanero M A et al. Lipid raft-targeted therapy in multiple myeloma. Oncogene, 2010; 29(26): 3748-3757.
61. Geilen C C, Haase R, Buchner K, Wieder T, Hucho F, Reutter W. The phospholipid analogue, hexadecylphosphocholine, inhibits protein kinase C in vitro and antagonises phorbol esterstimulated cell proliferation. Eur J Cancer, 1991; 27(12): 1650-1653.
62. 2 Binding on the Membrane Docking Geometry of PKCα C2 Domain: An EPR Sitedirected spin-labeling and relaxation study. Biochemistry, 2008, 47(32): 8301-8313.
63. Überall F, Oberhuber, Maly K, Zaknun J, Demuth L, Grunicke H H. Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity. Cancer Res, 1991; 51(3): 807-812.
64. Guerrero-Valero M, Ferrer-Orta C, Querol-Audi J, Marin-Vocente C, Fita I, Gómez-Fernández J C et al. Structural and mechanistic insights into the association of PKCα-C2 domain to PtdIns(4,5). PNAS, 2009; 106(16):6603-6607.
65. Shoji M, Raynor R L, Fleer E A, Eibl H, Vogler W R, Kou J F. Effects of hexadecylphosphocholine on protein kinase C and TPA-induced differentiation of HL60 cells. Lipid, 1991; 26(2): 145-149.
66. Chen R, Brady E, McIntyre T M. Human TMEM30a promotes uptake of antitumor and bioactive choline phospholipids into mammalian cells. J Immunol, 2011; 186(5): 3215-3225.
67. Fu D, Shi K, Wang Y. Bcl-2 plays a key role instead of mdr1 in the resistance to hexadecylphosphocholine in human epidermoid tumor cell line KB. Cancer Lett, 1999; 142(2): 147-153.
68. Alderliesten M C, Klarenbeek J B, Van der Luit A H, van Lummel M, Jones D R, Zerp S et al. Phosphoinositide phosphatase SHIP-1 regulates apoptosis induced by edelfosine, Fas ligation and DNA damage in mouse lymphoma cells. Biochem J, 2011; 440(1): 127-135.
69. van Blitterswijk W J, Klarenbeek J B, van der Luit A H, Alderliesten M C, van Lummel M, Verheij M. Fas/CD95 down-regulation in lymphoma cells through acquired alkyllysophospholipid resistance: partial role of associated sphingomyelin deficiency. Biochem J, 2009; 425(1): 225-234.
70. Herrmann D B, Neumann H A, Berdel W E, Heim M E, Fromm M, Boerner D, Bicker U et al. Phase I trial of the thioether phospholipid analogue BM 41.440 in cancer patients. Lipids 1987; 22 (11): 962-966.
71. Giantonio B J, Derry C, McAleer C, McPhillips J J, ÓDwyer P J. Phase I and Pharmacokinetic Study of the Cytotoxic Ether Lipid Ilmofosine Administered by Weekly Two-Hour Infusion in Patients with Advanced Solid Tumors. Clinical Cancer Research 2004;10:1282-1288.
72. Winkelmann M, Ebeling K, Strohmeyer G, Hottenrott G, Mechl Z, Berges W et al. Treatment results of the thioether lipid ilmofosine in patients with malignant tumours. J Cancer Res Clin Oncol 1992; 118(6):405-407.
73. Van Woolley P, Schultz C J, Rodriguez G I, Games R A, Rowe K W Jr, Dadey M L et al. A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma. Invest New Drugs 1996;14(2):219-22.
74. Planting A S, Stoter G, Verweij J. Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. Eur J Cancer, 1993; 29A(4): 518-519.
75. WHO. Technical Report Series 949: Control of the Leishmaniases. Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22-26 March 2010. Web. 7 May 2013. http://whqlibdoc.who.int/trs/WHO_TRS_949_en g.pdf
76. Herrmann D B, Pahlke W, Opitz H G, Bicker U. In vivo antitumor activity of ilmofosine. Cancer Treat Rev, 1990; 17: 247-252.
77. Eibl H, Unger C. Hexadecylphosphocholine: a new and selective antitumor drug. Cancer Treat Rev, 1990; 17: 233-242.
78. Jakubowiak A J, Richardson P G, Zimmerman T, Alsina M, Kaufman J L, Kandarpa M et al. Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. Br J Haematol, 2012; 158(4): 472-480.
79. Rübel A, Handrick R, Lindner L H, Steiger M, Eibl H, Budach W et al. The membrane targeted apoptosis modulators erucylphosphocholine and erucylphosphohomocholine increase the radiation response of human glioblastoma cell lines in vitro. Radiat Oncol, 2006. 1:6.
80. th).
81. Fu S, Hennessy B T, Ng C S, Ju Z, Coombes K R, Wolf J K et al. Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecologic Oncology, 2012; 126: 47-53.
82. Cho D C, Hutson T E, Samlowski W, Sportelli P, Somer B, Richards P et al. Two Phase 2 Trials of the Novel Akt Inhibitor Perifosine in Patients With Advanced Renal Cell Carcinoma After Progression on Vascular Endothelial Growth Factor-Targeted Therapy. Cancer 2012; 118: 6055-62.
83. Bendell J C, Nemunaitis J, Vukeja S J, Hagenstad C, Campos L T, Hermann R C et al. Randomized Placebo-controlled Phase II Trial of Perifosine Plus Capecitabine As Second-or Third-Line Therapy in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology 2011; 29 (33): 4394-4400.
84. Ghobrial I M, Roccaro A, Hong F, Weller E, Rubin N, Leduc R et al. Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia. Clin Cancer Res, 2010; 16(3): 1033-1041.
85. Unger C, Berdel W, Hanauske A R, Sundermann H, Engel J, Mross K. First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours. European Journal of Cancer, 2010; 46: 920-925.
86. Chee K G, Longmate J, Quinn D I, Chatta G, Pinski J, Twardowski P et al. The AKT Inhibitor Perifosine in Biochemically Recurrent Prostate Cancer: A Phase II California/Pittsburgh Cancer Consortium Trial. Clinical Genitourinary Cancer, 2007; 5(7): 433-437.
87. Marsh R W, Lima C M R, Levy D E, Mitchell E P, Rowland K M Jr, Benson A B 3rd. A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma. Am J Clin Oncol, 2007; 30(1): 26-31.
88. Argiris A, Cohen E, Karrison T, Esparaz B, Mauer A, Ansari R et al. A Phase II Trial of Perifosine, An Oral Alkylphospholipid, In Recurrent or Metastatic Head and Neck Cancer. Cancer Biology and Therapy, 2006; 5(7): 766-770.
89. Bailey H H, Mahoney M R, Ettinger D S, Maples W J, Fracasso P M, Traynor A M et al. Phase II Study of Daily Oral Perifosine in Patients With Advanced Soft Tissue Sarcoma. Cancer, 2006; 107: 2462-2467.
90. Ernst D S, Eisenhauer E, Wainman N, Davis M, Lohmann R, Baetz T et al. Phase II study of perifosine in previously untreated patients with metastatic melanoma. Investigational New Drugs, 2005; 23: 569-575.
91. Posadas EM, Gulley J, Arlen PM, Trout A, Parnes HL, Wright J, et al. A Phase II Study of Perifosine in Androgen Independent Prostate Cancer. Cancer Biology and Therapy, 2005; 4(10): 1133-1137.
92. Takai N, Ueda T, Ishii T, Kira N, Nishida M, Nasu K, et al. Erucylphosphocholine induces growth inhibition, cell cycle arrest, and apoptosis in human choriocarcinoma cells. Tumour Biol, 2011; 32(3): 569-74.
93. Rudner J, Ruiner CE, Handrick R, Eibl HJ, Belka C, Jendrossek V. The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation. Radiat Oncol, 2010 Nov 16;5:108.
94. Takai N, Ueda T, Nasu K, Narahara H. Erucylphosphocholine shows a strong antigrowth activity in human endometrial and ovarian cancer cells. Gynecol Oncol, 2008; 111(2): 336-43.
95. Kapoor V, Zaharieva MM, Das SN, Berger MR. Erufosine simultaneously induces apoptosis and autophagy by modulating the Akt-mTOR signaling pathway in oral squamous cell carcinoma. Cancer Lett, 2012; 319(1): 39-48.
96. Yosifov DY, Todorov PT, Zaharieva MM, Georgiev KD, Pilicheva BA, Konstantinov SM, et al. Erucylphospho-N, N, Ntrimethylpropylammonium (erufosine) is a potential antimyeloma drug devoid of myelotoxicity. Cancer Chemother Pharmacol, 2011; 67(1): 13-25.
97. Königs SK, Pallasch CP, Lindner LH, Schwamb J, Schulz A, Brinker R, et al. Erufosine, a novel alkylphosphocholine, induces apoptosis in CLL through a caspase-dependent pathway. Leuk Res, 2010; 34(8): 1064-9.
98. Berger MR, Tsoneva I, Konstantinov SM, Eibl H. Induction of apoptosis by erucylphospho-N, N, Ntrimethylammonium is associated with changes in signal molecule expressionand location. Ann N Y Acad Sci, 2003; 1010: 307-10.
99. Croft SL, Neal RA, Pendergast W, Chan JH. The activity of alkyl phosphorylcholines and related derivates against Leishmania donovani. Biochem Pharmacol, 1987; 36(16): 2633-2636.
100. Paladin Labs Inc. Application for Inclusion of Miltefosine on WHO Model List of Essential Medicines. 2010. Web 4 May 2013. http://www.who.int/selection_medicines/committ ees/expert/18/applications/Miltefosine_applicatio n.pdf
101. Government of India-National Vector Borne Disease Control Programme. Guideline on Use of Miltefosine. Web. 7 May 2013.
102. Escobar P, Matu S, Marques C, Croft SL. Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OH3 (edelfosine) and amphotericin B. Acta Trop, 2002; 81(2): 151-157.
103. Yardley V, Croft SL, De Doncker S, Dujardin JC, Koirala S, Rijal S, et al. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am J Trop Med Hyg, 2005; 73(2): 272-275.
104. Soto J, Rea J, Balderrama M, Toledo J, Soto P, Valda L, et al. Short Report: Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg, 2008; 78(2): 210-211.
105. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis, 2004; 38(9): 1266-1272.
106. Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: An open-label, non-inferiority, randomised controlled trial. Lancet, 2011; 377: 477-486.
107. Varela M RE, Villa-Pulgarin JA, Yepes E, Müller I, Modolell M, Muñoz DL, et al. In vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasites. PloS Negl Trop Dis, 2012; 6(4):e1612.
108. Cabrera-Serra MG, Lorenzo-Morales J, Romero M, Valladares B, Piñero JE. In vitro activity of perifosine: a novel alkylphospholipid against the promastigote stage of Leishmania species. Parasitol Res, 2007; 100(5): 1155-1157.
109. Cabrera-Serra MG, Valladares B, Piñero JE. In vivo activity of perifosine against Leishmania amazonensis. Acta Trop, 2008; 108: 20-25.
110. Rihl M, Stoll M, Ulbricht K, Bange FC, Schmidt RE. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe. J Infect, 2006; 53(1): e25-e27.
111. Schraner C, Hasse B, Hasse U, Baumann D, Faeh A, Burg G, et al. Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1. Clin Infect Dis, 2005; 40(12): e120-e124.
112. Eue I. Hexadecylphosphocholine selectively upregulates expression of intracellular adhesion molecule-1 and class I major histocompatibility complex antigen in human monocytes. J Exp Ther Oncol, 2002; 2(6): 333-336.
113. Hochhuth CH, Vehmeyer K, Eibl H, Unger C. Hexadecylphosphocholine induces interferongamma secretion and expression of GM-CSF mRNA in human mononuclear cells. Cell Immunol, 1992; 141(1): 161-168.
114. Garg R, Tremblay MJ. Miltefosine represses HIV-1 replication in human dendritic cell/T-cell cocultures partially by inducing secretion of type-I interferon. Virology, 2012; 432(2): 271-276.
115. Chugh P, Bradel-Tretheway B, Monteiro-Filho CM, Planelles V, Maggirwar SB, Dewhurst S, et al. Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy. Retrovirology, 2008; 5: 11.
116. Fries DS, Fairlamb, AH. Antiprotozoal Agent, in Abraham DJ(ed), Burger's Medicinal Chemistry, Drug Discovery and Development. 6th ed., John Wiley & Sons, New York, NY, pp 1033-1087, 2003.
117. Olliaro P, Lazdins J, Guhl F. Developments in the treatment of leishmaniasis and trypanosomiasis. Expert Opion Emerg Drugs, 2002; 7(1): 61-67.
118. Croft SL, Snowdon D, Yardley V. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J Antimicrob Chemother, 1996; 38(6): 1041-1047.
119. Saraiva VB, Gibaldi D, Previato JO, Mendonça-Previato L, Bozza MT, Freire-De-Lima CG, et al. Proinflammatory and cytotoxic effects of hexadecylphosphocoline (miltefosine) against drug-resistant strains of Trypanosoma cruzi. Antimicrob Agents Chemother, 2002; 46(11): 3472-3277.
120. Luna KP, Hernández IP, Rueda CM, Zorro MM, Croft SL, Escobar P. In vitro susceptibility of Trypanosoma cruzi strains from Santander, Colombia, to hexadecylphosphocholine (miltefosine), nifurtimox and benznidazole. Biomedica, 2009; 29(3): 448-455.
121. Konstantinov SM, Kaminsky R, Brun R, Berger MR, Zillmann U. Efficacy of anticancer alkylphosphocholines in Trypanosoma brucei subspecies. Acta Trop, 1997; 64: 145-154.
122. Lira R, Contreras LM, Rita RM, Urbina JA. Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite Trypanosoma cruzi: Potentiation of in vitro activity by the sterol biosynthesis inhibitor ketoconazole. J Antimicrob Chemother, 2001; 47(5): 537-546.
123. Santa-Rita RM, Lira R, Barbosa HS, Urbina JA, de Castro SL. Anti-proliferative synergy of lysophospholipid analogues and ketoconazole against Trypanosoma cruzi (Kinetoplastida: Trypanosomatidae): cellular and ultrastructural analysis. J Antimicrob Chemother, 2005; 55(5): 780-784.
124. Seifert K, Duchêne M, Wernsdorfer WH, Kollaritsch H, Scheiner O, Wiedermann G, et al. Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica. Antimicrob Agents Chemother, 2001; 45(5): 1505-1510.
125. Walochnik J, Duchêne M, Seifert K, Obwaller A, Hottkowitz T, Wiedermann G, et al. Cytotoxic activities of alkylphosphocholines against clinical isolates of Acanthamoeba spp. Antimicrob Agents Chemother, 2002; 46(3): 695-701.
126. Blaha C, Duchêne M, Aspöck H, Walochnik J. In vitro activity of hexadecylphosphocholine (miltefosine) against metronidazole-resistant and-susceptible strains of Trichomonas vaginalis. J Antimicrob Chemother, 2006; 57(2): 273-278.
127. Allan D, Payares G, Evans WH. The phospholipid and fatty acid composition of Schistosoma mansoni and of its purified tegumental membranes. Mol Biochem Parasitol, 1987; 23(2): 123-128.
128. Faghiri Z, Skelly P J. The role of tegumental aquaporin from the human parasitic worm, Schistosoma mansoni, in osmoregulation and drug uptake. FASEB J, 2009; 23(8): 2780-2789.
129. López-Arrieta J, Schneider L. Metrifonate for Alzheimer's disease. Cochrane Database of Syst Rev (1): CD003155 2008. doi:10.1002/ 14651858.CD003155.pub3.
130. Eissa MM, El-Azzouni MZ, Amer EI, Baddour NM. Miltefosine, a promising novel agent for schistosomiasis mansoni. Int J Parasitol, 2011; 41(2): 235-242.
131. Widmer F, Wright LC, Obando D, Handke R, Ganendren R, Ellis DH, et al. Hexadecylphosphocholine (miltefosine) has broad-sprectum fungicidal activity and is efficacious in a mouse model of Cryptococcosis. Antimicrob Agents Chemother, 2006; 50(2): 414-421.
132. Lux H, Heise N, Klenner T, Hart D, Opperdoes FR. Ether-lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether-lipid analogues in Leishmania. Mol Biochem Parasitol, 2000; 111: 1-14.
133. Santangelo R, Zoellner H, Sorrell T, Wilson C, Donald C, Djordjevic J, et al. Role of extracellular phospholipases and mononuclear phagocytes in dissemination of Cryptococcosis in a murine model. Infect Immun, 2004; 72(4): 2229-2239.
134. Obando D, Widmer F, Wright LC, Sorrell TC, Jolliffe KA. Synthesis, antifungal and antimicrobial activity of alkylphospholipids. Bioorg Med Chem, 2007; 15(15): 5158-5165.
135. Lukáč M, Garajová M, Mrva M, Bukovský M, Ondriska F, Máriássy E, et al. Relationship between aggregation properties and antimicrobial activities of alkylphosphocholines with branched alkyl chains. Int J Pharm, 2012; 423(2): 247-256.
136. Vila TV, Ishida K, de Souza W, Prousis K, Calogeropoulou T, Rozental S. Effect of alkylphospholipids on Candida albicans biofilm formation and maturation. J Antimicrob Chemother, 2013; 68: 113-125.
137. Tong Z, Widmer F, Sorrell TC, Guse Z, Jolliffe KA, Halliday C, et al. In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes. Antimicrob Agents Chemother, 2007; 51(6): 2219-2222.
138. Höltje JV, Tomas A. Lipoteichoic acid: a specific inhibitor of autolysin activity in pneumococcus. Proc Natl Acad Sci U S A, 1975; 72(5): 1690-1694.
139. Le Maire M, Champeil P, Moller J V. Interaction of membrane proteins and lipids with solubilizing detergents. Biochim Biophys Acta, 2000; 1508: 86-111.
140. Llull D, Rivas L, García E. In vitro bactericidal activity of the antiprotozoal drug miltefosine against Streptococcus pneumoniae and other pathogenic Streptococci. Antimicrob Agents Chemother, 2007; 51(5): 1844-1848.
141. Huelves L, Del Prado G, Gracia M, Rodríguez-Cerrato V, Ponte C. In vitro and in vivo activity of miltefosine against penicillin-sensitive and-resistant Streptococcus pneumoniae strains. J of Chemother, 2008; 20(4): 441-444.
142. Eibl KH, Liegl R, Kernt M, Priglinger S, Kampik A. Alkylphosphocholines as a potential pharmacologic prophylaxis for posterior capsule opacification. J Cataract Refract Surg, 2009; 35(5): 900-905.
143. Eibl KH, Wertheimer C, Kernt M, Wolf A, Kook D, Haritoglou C, et al. Alkylphosphocholine for intraocular lens coating. J. Cataract Refract Surg, 2013; 39: 438-445.
144. Grosman N. Effects of the ether phospholipid AMG-PC on mast cells are similar to that of the ether lipid AMG but different from that of the analogue hexadecylphosphocholine. Immunopharmacology, 1991; 22(1): 39-47.
145. Weller K, Artuc M, Jennings G, Friedrichson T, Guhl S, dos Santos RV, et al. Miltefosine inhibits human mast cell activation and mediator release both in vitro and in vivo. J Invest Dermatol, 2009; 129(2): 496-498.
146. Arthur G, Bittman R. The inhibition of cell signaling pathways by antitumor ether lipids. Biochim Biophys Acta, 1998; 1390(1): 85-102.
147. Magerl M, Rother M, Bieber T, Biedermann T, Brasch J, Dominicus R, et al. Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamineresistant chronic spontaneous urticaria. J Eur Acad Dermatol Venereol, 2012; 27(3): e363-e369.
148. th Brazilian Simposium on Medicinal Chemistry, RS, Brazil; http://www.ufrgs.br/brazmedchem2012/docs/Bra zmedchem_ebook.pdf, 2012.
149. th Brazilian Simposium on Medicinal Chemistry, RS, Brazil; http://www.ufrgs.br/brazmedchem2012/docs/Bra zmedchem_ebook.pdf, 2012.
150. Sá M M, Pasqualoto, K. F. M., Modestia, S. M., Rangel-Yagui, C. O. Alkylphosphocholines as promising antitumor agents: Exploring the role of structural features on the hemolytic potential. Mol Inf (In Press), 2013.